Ann: Immutep Corporate Presentation, page-7

Triebel mentioned the phase3 in a recent interview, I think. All depends on coming OS results and discussions with regulators, I guess.
Immutep could take the ph3 forward but would need an additional raise during the trial. If the benefit is meaningful from the ph2 it would be in the companies interest to proceed on their own, imo, because we are already doing so many trials in partnership with others. They have the experience now, too.

The big ticket item is auto-immune. The addressable market is many times bigger than anything they are doing in oncology. Unfortunately it is taking too long to get this into the clinic, imo. I hope we get some clear signs of progress here soon.